, Tracking Stock Market Picks
Enter Symbol:
Rating: STJ
Sell $47

St. Jude Medical, Inc. (NYSE: STJ) reiterated to Sell with price target $47 by Canaccord Genuity

Thursday,  Oct 16, 2014  9:25 AM ET by Dave Ficere

Canaccord Genuity reiterated St. Jude Medical, Inc. (NYSE: STJ) to Sell with
price target $47. Previously Canaccord Genuity rated Sell with price target $51 St. Jude Medical, Inc. (NYSE: STJ) on 01/23/2014, when the stock price was $64.35.

St. Jude Medical, Inc. (St. Jude)develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and implantable neurostimulation devices for the management of chronic pain. The Company operates in four business segments: Cardiac Rhythm Management (CRM), Cardiovascular (CV), Atrial Fibrillation (AF) and Neuromodulation Systems (Neuro). On July 3, 2008, the Company completed the acquisition of EP MedSystems, Inc. On December 19, 2008, St. Jude acquired Radi Medical Systems. On December 22, 2008, St. Jude acquired MediGuide Inc.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy